Turan Çağrı, Öner Ümran
Department of Dermatology and Venereology, Medical Park Ankara Hospital, Ankara, Turkey.
Department of Dermatology and Venereology, Kastamonu University School of Medicine, Kastamonu, Turkey.
Dermatol Pract Concept. 2023 Jan 1;13(1):e2023012. doi: 10.5826/dpc.1301a12.
Isotretinoin (ISO)-associated cheilitis is the most common side effect and the most common reason for discontinuation of ongoing therapy. So, various lip balms are also routinely recommended for all patients.
We aimed to investigate the effectiveness of local intradermal injections (mesotherapy) of dexpanthenol into the lips to prevent ISO-associated cheilitis.
This pilot study was conducted on patients over the age of 18 using ISO (about 0.5 mg/kg/day). All patients were prescribed only hamamelis virginiana distillate in ointment form as a lip balm. In the mesotherapy group (n=28), 0.1 ml of dexpanthenol was injected into each lip tubercle (4 points total) to the submucosal level. The patients in the control group (n=26) used only the ointment. "ISO cheilitis grading scale (ICGS)" was used in the evaluation of ISO-associated cheilitis. The patients were followed for 2 months.
Although there was an increase in ICGS scores in the mesotherapy group compared to the baseline, no statistically significant change was observed after treatment (p=0.545). However, in the control group, there was a statistically significant increase in ICGS scores in the 1st and 2nd months compared to the baseline (p<0.001). Lip balms were needed significantly less frequently in the mesotherapy group compared to the control, both in the 1st and 2nd months (p=0.006, p=0.045; respectively).
Lip mesotherapy with dexpanthenol will be a useful option for preventing ISO-associated cheilitis because of its easy application, cost-effectiveness, low complication risk, and high patient satisfaction.
异维甲酸（ISO）相关的唇炎是最常见的副作用，也是中断正在进行的治疗的最常见原因。因此，各种润唇膏也常规推荐给所有患者。
我们旨在研究在唇部进行泛醇皮内注射（中胚层疗法）预防ISO相关唇炎的有效性。
本前瞻性研究针对使用ISO（约0.5mg/kg/天）的18岁以上患者开展。所有患者仅被开具了软膏形式的北美金缕梅馏出液作为润唇膏。在中胚层疗法组（n = 28）中，将0.1ml泛醇注射到每个唇结节（共4个点）至黏膜下层。对照组（n = 26）的患者仅使用软膏。使用“ISO唇炎分级量表（ICGS）”评估ISO相关唇炎。对患者进行2个月的随访。
虽然中胚层疗法组的ICGS评分与基线相比有所增加，但治疗后未观察到统计学上的显著变化（p = 0.545）。然而，在对照组中，与基线相比，第1个月和第2个月的ICGS评分有统计学上的显著增加（p < 0.001）。与对照组相比，中胚层疗法组在第1个月和第2个月使用润唇膏的频率明显更低（分别为p = 0.006，p = 0.045）。
由于泛醇唇部中胚层疗法应用简便、成本效益高、并发症风险低且患者满意度高，它将是预防ISO相关唇炎的一个有用选择。
